EPIPEN Act

The EPIPEN Act (HR 5139) requires most health insurance plans to cover epinephrine delivery systems (like EpiPens, nasal sprays, or sublingual devices approved by the FDA) without applying deductibles and limiting out-of-pocket costs to $60 per package of two devices. It directly affects people with severe allergies who rely on these emergency treatments, ensuring they pay no more than $60 per two-device package. The bill mandates that any cost-sharing payments count toward the plan’s annual out-of-pocket maximum, though plans may charge higher fees for out-of-network providers. The requirements will take effect for plan years beginning January 1, 2026.